Episode 52
Biotech Hangout
00:00
The Effects of EGFR Mutant Lung Cancer on Overall Survival
It's not biotech obviously and this is a biotech hangout but it really speaks to say it comes to the same issue that that Josh was talking about where you have such a dichotomy or or black-and-white approach I could say to people's attitudes toward a drug. This is targeted targeting is EGFR mutant lung cancer and putting aside the efficacy that we've seen in metastatic disease they also showed over three years ago or more now I can't remember exactly a very significant reduction in the risk of disease progression or disease recurrence with adjuvant use. So again a good positive news today and a windfall patients and I don't even Adam I think commented on it
Transcript
Play full episode
